Keyphrases
Metastatic Castration-resistant Prostate Cancer (mCRPC)
79%
Prostate Cancer
77%
Advanced Prostate Cancer
63%
Overall Survival
46%
Bladder Cancer
45%
Minimal Residual Disease
44%
Clear Cell Renal Cell Carcinoma (ccRCC)
33%
Muscle-invasive Bladder Cancer
33%
Abiraterone
33%
CDK12
33%
Enzalutamide
29%
Chemotherapy
29%
Tumor
28%
Tumor DNA
24%
Curative Intent
23%
DNA Detection
22%
Radical Cystectomy
22%
Essential Pathway
22%
Transcriptomic Characterization
22%
Epigenetics
22%
Progression Markers
22%
Survival Outcomes
22%
Comorbid Diseases
22%
Immune Checkpoint Blockade
20%
Upper Tract Urothelial Carcinoma
19%
Cancer Patients
17%
Carboplatin
16%
Clinical Trial Development
14%
PARP Inhibitor (PARPi)
14%
Circulating Tumor DNA (ctDNA)
14%
Positron Emission Tomography-computed Tomography (PET-CT)
13%
Confidence Interval
13%
Tumor Microenvironment
13%
Urine Cell-free DNA
13%
Treatment Outcome
13%
Multi-omics
13%
Radiotherapy Alone
13%
Proteogenomics
13%
Tumor Evolution
13%
Single-nucleus RNA Sequencing
13%
Spatial Transcriptomics
13%
BRCA1, BRCA2
13%
Clinical Trial Design
13%
Solid Tumors
13%
Metastatic Urothelial Carcinoma
12%
Multivariable
12%
Chemoradiotherapy
12%
Liquid Biopsy
11%
Combination Immunotherapy
11%
Cyclin-dependent Kinase 12
11%
Medicine and Dentistry
Prostate Cancer
85%
Neoplasm
60%
Minimal Residual Disease
44%
Overall Survival
41%
Castration Resistant Prostate Cancer
39%
Diseases
38%
Muscle Invasive Bladder Cancer
33%
Bladder Cancer
32%
Radiation Therapy
27%
Transitional Cell Carcinoma
26%
Bladder
26%
Cohort Analysis
24%
Immunotherapy
23%
Cystectomy
22%
Chemoradiotherapy
22%
Clear Cell Renal Cell Carcinoma
22%
Urothelial Cancer
22%
Bladder Tumor
19%
Malignant Neoplasm
19%
Immune Checkpoint Blockade
16%
Circulating Tumor DNA
15%
Positron Emission Tomography-Computed Tomography
14%
Clinical Trial
14%
Cisplatin
13%
Cell-Free DNA
13%
Liquid Biopsy
13%
Homologous Recombination
12%
Tamsulosin
11%
Enzalutamide
11%
Abiraterone
11%
Solid Malignant Neoplasm
11%
Cyclin-Dependent Kinase
11%
Coronary Artery Calcification
11%
Therapy Delay
11%
Extrapulmonary Tuberculosis
11%
4 Iodo 2,5 Dimethoxyamphetamine
11%
PARP1
11%
Brain Metastasis
11%
Recombination Repair
11%
Transcriptomics
11%
Cardiovascular Risk
11%
Robot-Assisted Prostatectomy
11%
Lung Tuberculosis
11%
Gene Expression
11%
Carcinomatous Peritonitis
11%
Crohn's Disease
11%
Otitis Media
11%
Avelumab
11%
Proteomics
11%
Proteogenomics
11%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Overall Survival
46%
Diseases
40%
Castration Resistant Prostate Cancer
39%
Abiraterone
33%
Neoplasm
30%
Enzalutamide
29%
Bladder Cancer
29%
Malignant Neoplasm
27%
Clinical Trial
27%
Renal Cell Carcinoma
22%
Chemoradiation Therapy
22%
Immunotherapy
22%
Chemotherapy
21%
Bladder Tumor
19%
Adverse Event
16%
Transitional Cell Carcinoma
15%
Cardiovascular Risk
13%
Clinical Trial Design
13%
Prostate Specific Antigen
12%
Prostate Disease
11%
Extrapulmonary Tuberculosis
11%
Minimal Residual Disease
11%
Myeloma
11%
Bone Metastasis
11%
Zoledronic Acid
11%
Coronary Artery Calcification
11%
Tamsulosin
11%
Multiple Myeloma
11%
Cyclin Dependent Kinase
11%
Muscle Invasive Bladder Cancer
11%
Pazopanib
11%
Crohn's Disease
11%
Lung Tuberculosis
11%
Otitis Media
11%
Endocrine Therapy
11%
FDA Adverse Event Reporting System
11%
Radioligand
11%
Cardiovascular Disease
9%
Gonadorelin Antagonist
8%
Recurrent Disease
8%
Tumor Microenvironment
8%
Metastatic Breast Cancer
7%
Combination Therapy
7%
Monotherapy
6%
Gonadorelin Agonist
6%
Androgen Receptor
6%
Congestive Heart Failure
6%
Night Sweat
5%
Otorrhea
5%